http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Rougier, P. (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
-
-
Shuqin Zan,Craig B. Wood,Guillermo W. Rougier,Liyong Jin,Jun Chen,Charles R. Schaff 한국고생물학회 2006 고생물학회지 Vol.22 No.1
중국 길림성의 Gongzhuling 시 근처의 새로운 백악기 화석지에서 산출된 화석은 두개의 불완전한 포유류 하악골을 포함하는데 이 표본은 태반류 Zalambdalestidae과에 속하는 새로운 속과 종이다. 화석지는 Songliao분지의 넓게 분포하는 Quantou층의 가창자리에 위치하는데 Songliao분지의 시대는 Aptian~Cenomanian으로 알려져 있다. 그러나 Quantou층이 Cenomanian 보다 더 젊을 것 같지는 않다. 두 하악골은 크고 납작한 첫 번째 앞니를 갖고 있는데 Kulbeckia kulbecke같은 종과 비교해 보면 원시적이고 진화적인 특징들이 흥미롭게 섞여 있다. 예를 들면, Gongzhuling 표본은 5개의 앞어금니 (거의 완전한 어금니 형태의 앞어금니)와 단지 3개의 앞니, 그리고 한 개의 낮고 단 뿌리의 송곳니를 가진다. 5번째 앞어금니와 첫 번째 어금니의 trigonids는 상대적으로 눌리지 않고 열려있는 형태다. 이 화석지는 “중기” 백악기 척추화석들에 대한 새로운 정보를 확보할 중요한 장소로 알려지게 될 것이며 가까운 미래에 이곳에서 새로운 포유류, 공룡, 그리고 다른 표본들이 기재될 것이다. Fossil specimens from a new Cretaceous locality near Gongzhuling City in Jilin Province, China, include two incomplete mammalian dentaries which represent a new genus and species referable to the eutherian family Zalambdalestidae. The locality is in basin-margin outcrops of the Quantou Formation, which is widely spread in the subsurface of Songliao Basin and which has been assigned ages ranging from the Aptian to the Cenomanian stages of the Cretaceous; it seems unlikely that the Quantou Formation could be younger than Cenomanian. Both dentaries possess an enlarged, procumbent first incisor combined with an interesting mosaic of both plesiomorphic and derived dental characters compared to taxa such as Kulbeckia kulbecke. For example, the new Gongzhuling specimens appear to show five premolars (including an almost fully molariform ultimate premolar) combined with only three incisors and a low but single-rooted canine. The trigonids on p5 and m1 are relatively open and non-compressed. This locality is likely to emerge as an important source of new information on "middle" Cretaceous vertebrates as additional mammalian, dinosaurian, and other specimens are described from it in the near future.
-
Al-Batran, S.-E.,Van Cutsem, E.,Oh, S. C.,Bodoky, G.,Shimada, Y.,Hironaka, S.,Sugimoto, N.,Lipatov, O. N.,Kim, T.-Y.,Cunningham, D.,Rougier, P.,Muro, K.,Liepa, A. M.,Chandrawansa, K.,Emig, M.,Ohtsu, A Oxford University Press 2016 Annals of Oncology Vol.27 No.4
<P><B>Background</B></P><P>The phase III RAINBOW trial demonstrated that the addition of ramucirumab to paclitaxel improved overall survival, progression-free survival, and tumor response rate in fluoropyrimidine–platinum previously treated patients with advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma. Here, we present results from quality-of-life (QoL) and performance status (PS) analyses.</P><P><B>Patients and methods</B></P><P>Patients with Eastern Cooperative Oncology Group PS of 0/1 were randomized to receive ramucirumab (8 mg/kg i.v.) or placebo on days 1 and 15 of a 4-week cycle, with both arms receiving paclitaxel (80 mg/m<SUP>2</SUP>) on days 1, 8, and 15. Patient-reported outcomes were assessed with the QoL/health status questionnaires EORTC QLQ-C30 and EQ-5D at baseline and 6-week intervals. PS was assessed at baseline and day 1 of every cycle. Time to deterioration (TtD) in each QLQ-C30 scale was defined as randomization to first worsening of ≥10 points (on 100-point scale) and TtD in PS was defined as first worsening to ≥2. Hazard ratios (HRs) for treatment effect were estimated using stratified Cox proportional hazards models.</P><P><B>Results</B></P><P>Of the 665 patients randomized, 650 (98%) provided baseline QLQ-C30 and EQ-5D data, and 560 (84%) also provided data from ≥1 postbaseline time point. Baseline scores for both instruments were similar between arms. Of the 15 QLQ-C30 scales, 14 had HR < 1, indicating similar or longer TtD in QoL for ramucirumab + paclitaxel. Treatment with ramucirumab + paclitaxel was also associated with a delay in TtD in PS to ≥2 (HR = 0.798, <I>P</I> = 0.0941). Alternate definitions of PS deterioration yielded similar results: PS ≥ 3 (HR = 0.656, <I>P</I> = 0.0508), deterioration by ≥1 PS level (HR = 0.802, <I>P</I> = 0.0444), and deterioration by ≥2 PS levels (HR = 0.608, <I>P</I> = 0.0063). EQ-5D scores were comparable between treatment arms, stable during treatment, and worsened at discontinuation.</P><P><B>Conclusion</B></P><P>In patients with previously treated advanced gastric/GEJ adenocarcinoma, addition of ramucirumab to paclitaxel prolonged overall survival while maintaining patient QoL with delayed symptom worsening and functional status deterioration.</P><P><B>ClinicalTrials.gov</B></P><P>NCT01170663.</P>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
